Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

BECHETARY OF THE SENATE 99 AUG 13 AM 11: 21

H.D.

_____ Page 1 of 20

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

Registrant Name Nevertis		
•	Suile 725 DC 20004	
3. Principal Place of Business (if different from line 2)	``````````````````````````````````````	
City State/Zip (or Country)		•
4. Contact Name E-ma	al (aptional)	5. Sensite (D.#
Rachel King 202/293-3019		
7. Client Name [] Self		6. House ID #
Novartis Corporation		33589000
Check if this is a Termination Report >> Terminatio INCOME OR EXPENSES - Complete Either	r Line 12 OR Line 13	II. No Lobbying Activity
12. Lobbying Firms	13. Organiza	
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying acti period were:	vities for this reporting
Less than \$10,000 ()	Less than \$10,000 ()	
\$10,000 or more	\$10,000 or more 86 >> \$	5940,000.00
Income (nearest \$20.000) Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client	14. REPORTING METHOD, Checaccounting method, See instructions I	Expenses (scares) \$20,000) ok box to indicate expense for description of options.
(including all payments to the registrant by any other entity	Method A. Reporting amounts u	sing LDA definitions only
for lobbying activities on behalf of the client).	Method B. Reporting amounts u the Internal Revenue	
/	Method C. Reporting amounts u Internal Revenue Cor	nder section 162(e) of the de
ignature Michel Willy	Date	8/4/99
rinted Name and Tale Rachel King - Vice President		Page 1 of 20

Registrant Name:	Novartis		
Client Name:	Novartis Corporation		
engaged in lobbyin	IVITY. Select as many codes as necessary g on behalf of the client during the reporting tested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide i.	
 General issue 	(**************************************		
59 Fed. Reg, Food Quality Insect Resist Genetically I	cticide, Fungicide & Rodenticide Act 60412 (11/24/96) Atrazine, Simazine and Protection Act ance Management Ingineered Crops Approprations Bill	d Cyanazine: Nutice of Initiation of Special Review	
Department	iongress and Federal agencies contacted of Agriculture al Protection Agency presentatives	☐ Check if None	
18. Name of each	individual who acted as a lobbyist in this i	issue area	
Name		Covered Official Position (if applicable)	New
Name Rentley, Lisa		Covered Official Position (if applicable)	New No
		Covered Official Position (if applicable)	
Rentley, Łisa		Covered Official Position (if applicable)	No
Rentley, Lisa King, Rachel		Covered Official Position (if applicable)	No No
Rentley, Lisa King, Rachel		Covered Official Position (if applicable)	No No
Rentley, Lisa King, Rachel		Covered Official Position (if applicable)	No No
Hentley, Lisa King, Rachel Muldnon, Jo 19. Interest of eac Novartis AG	h foreign entity in the specific issues listed		No No No
Hentley, Lisa King, Rachel Muldnon, Jo 19. Interest of eac Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, either AG, as its parent, will benefit.	on line 16 above	No N
Hentley, Lisa King, Rachel Muldnon, Jo 9. Interest of eac Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, either AG, as its parent, will benefit.	oa line 16 above	No No No Oration, so

Registrant Name;	Novartis		
Client Name:	Nevartis Corporation		
engaged in lobbyic	IVITY. Select as many codes as necessary g on behalf of the client during the reported rested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registranting period. Using a separate page for each code, provide	
15. General issue 16. Specific Lobb	(k k k k		
17. House(s) of C	ongress and Federal agencies contacted	★ Check if None	
18. Name of each	individual who acted as a lobbyist in this i	issue area	
Name		Covered Official Position (if applicable)	New
		WWWWWAIIA	
		VIV	
89. Interest of eac	h foreign entity in the specific issues listed	on line 16 above X Check if None	
		Date	
Printed Name and	Title Rachel King - Vice President	Pap	ge 3 of 20

174RI	strant Name:	Novartis		
Clies	nt Name;	Nevartis Corporation		
enga	ged in lobhyin	IVITY. Select as many codes as necessary g on behalf of the client during the reports ested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide I.	
15.	General issue	area code <u>SUD</u> (one per page)		
16.	Specific Lobb Appropriatio Administratio			
17.	House(s) of C House of Rep Senate	ongress and Federal agencies contacted resentatives	☐ Check if None	
18.	Name of each	individual who acted as a lobbyist in this		
	Name		Covered Official Position (if applicable)	
			Covered Official (Ostoon (i) approache)	New
	Bumbsugh, Į	eborah	covered official content (it approache)	New No
		Peborah	Covered Official Country (it approache)	·/
	Bumbsugh, Į	Peborah	Covered Official Country (it approache)	No
	Bumbsugh, Į	Peborah	Covera Official Ostron (it approache)	No
	Bumbsugh, Į	Peborah	Covera Official Ostron (in appreciate)	No
	Bumbsugh, Į	Deborah	Covera Official Ostron (in appreciate)	No
19.	Bumbaugh, E Elkin, James Elkin, James Interest of cac Novartis AG	h foreign entity in the specific issues listed		No No
	Bumbaugh, E Elkin, James Elkin, James Interest of cac Novartis AG toe Novartis	h foreign entity in the specific issues listed To the degree that public policies, eithe AG, as its parent, will benefit.	on line 16 above C Check if None r laws or regulations, commercially benefit Novartis Cor	No No No Poraties, so
Sign	Bumbaugh, E Elkin, James Elkin, James Interest of cac Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, eithe AG, as its parent, will benefit.	I on line 16 above C) Check if None	No No No poraties, so

подизиан	it Name:	Novartis		
Client Na	me:	Nevartis Corporation	- William A	
engaged is	in lobbying	VITY. Select as many codes as necessary on behalf of the client during the reporting ested, Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant g period. Using a separate page for each code, provide	
IS. Gene	ierał issue a	area code CAW (one per page)		
Spec	cific Lobby	ing issues		
		·		
		•		
17. Hou	ise(s) of Co	ongress and Federal agencies contacted		
	,	The state of the s	Re Vision II (Total)	
18. Nam	ne of each	individual who acted as a lobbyist in this is	SSEC ATER	
18. Nam		individual who acted as a lobbyist in this is	Suc area Covered Official Position (if applicable)	New
		individual who acted as a lobbyist in this is		New
		individual who acted as a lobbyist in this is		New
		individual who acted as a lobbyist in this is		New
		individual who acted as a lobbyist in this is		New
		individual who acted as a lobbyist in this is		New
		individual who acted as a lobbyist in this is		New
		individual who acted as a lobbyist in this is		New
		individual who acted as a lobbyist in this is		New
		individual who acted as a lobbyist in this is		New
Nam	ne		Covered Official Position (if applicable)	New
Nam	ne	t foreign entity in the specific issues listed	Covered Official Position (if applicable)	New
Nam	ne		Covered Official Position (if applicable)	New
Nam	ne		Covered Official Position (if applicable)	New
Nam	rest of cacl	a foreign entity in the specific issues listed	Covered Official Position (if applicable)	
Nam	rest of cacl	t foreign entity in the specific issues listed	On line 16 above Check if Nane Date	
Nam	rest of cacl	t foreign entity in the specific issues listed	On line 16 above Check if None	

LOBBYING ACTO	Nevartis Corporation		
LOBBYING ACTI mgaged in lobbying			
nformation as reque	VITY, Select as many codes as necessar, on behalf of the client during the reporti sted. Attach additional page(s) as needer	y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provid l.	3
Food Quality I	ing issues i0412 (11/24/96) Atrazine, Simazine an	d Cyanazine: Notice of Inititation of Special Review	
Department of Department of Department of	Labor Slate I Protection Agency Administration	☐ Check if None	
8. Name of each is	ndividual who acted as a lobbyist in this	issue arca	
Name		Covered Official Position (if applicable)	New
Muldoon, Joe			No
			00000
Novartis AG T	foreign entity in the specific issues listed to the degree that public policies, either G, as its parent, will benefit.	f on line 16 above Check if None r laws or regulations, commercially benefit Novartis C	Corporation, so
		Date	·····
rinted Name and Tit	tie Rachel King - Vice President	P	age 6 of 20

Registrant Name:	Novartis		
Client Name:	Nevartis Corporation		
engaged in tobbyi	TIVITY. Select as many codes as necessary to refle ng on behalf of the client during the reporting perio- mested. Attach additional page(s) as needed.	et the general issue areas in which the registrant d. Using a separate page for each code, provide	·
15. General issu	e area code <u>CPT</u> (one per page)		
H.R. 2100, . H.R. 2654, I	bying issues American Inventors Protection Act of 1999, Anti-Tampering Act of 1999, Patent Law Reform Act, . 1598, Patent Fairness Act of 1999,		
	Congress and Federal agencies contacted spresentatives	Check if None	
18. Name of eac	h individual who acted as a lobbyist in this issue are	a ered Official Position (if applicable)	. New
Casserly, D	an .		No
Drake, Dav	id .		No
Elkin, Jamo	5		Ne
Novartis AC	ich foreign entity in the specific issues listed on line To the degree that public policies, either laws o AG, as its parent, will benefit	16 above	erporation, se
Printed Name and	Title Rachel King - Vice President	Pa	ge 7 of 20
		•	

Registrant N	ame: <u>Novartis</u>		
Client Name	Novartis Corporation		
engaged in le	GACTIVITY. Select as many codes as necessar obbying on behalf of the client during the report as requested. Attach additional page(s) as neede	y to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide d.	
	issue area code <u>ENV</u> (one per page)	
H.R. 10	: Lobbying issues i57, Children's Environmental Protection and / H.R. 1386, Superfund Reform,	d Right to Know Act of 1999,	
	s) of Congress and Federal agencies contacted of Representatives	☐ Check if None	
18. Name o	f each individual who acted as a tobbyist in this	issue area	
Name		Covered Official Position (if applicable)	New
Name Drake,	David	Covered Official Position (if applicable)	
	David	Covered Official Position (if applicable)	New No
	David	Covered Official Position (if applicable)	
	David	Covered Official Position (if applicable)	
	David	Covered Official Position (if applicable)	
	David	Covered Official Position (if applicable)	
	David	Covered Official Position (if applicable)	
	David	Covered Official Position (if applicable)	
Drake,	of cach foreign entity in the specific issues lister		No No
Drake, 19. Interest Nevarti tee Nov	of each foreign entity in the specific issues listers is AG To the degree that public policies, either artis AG, as its parent, will benefit	d on line 16 above	No No
Drake, Drake, 19. Interest Nevartite Nevarti	of each foreign entity in the specific issues listers and the degree that public policies, either artis AG, as its parent, will benefit	d on line 16 above	No No
Drake, Drake, 19. Interest Nevartite Nevarti	of each foreign entity in the specific issues listers and the degree that public policies, either artis AG, as its parent, will benefit	d on line 16 above	No No

Reg	istrant Name:	Novartis	
Clie	nt Name:	Novartis Corporation	
епда	iged in lobbyin	TVITY. Select as many codes as accessary to reflect the general issue areas in which the registrant ig on behalf of the client during the reporting period. Using a separate page for each code, provide uested. Attach additional page(s) as needed.	
15. 16.	Specific Lobb S. 1155, H.R. S. 251, S. 860 59 Fed. Reg. Food Quality GMO Labeli Juice HACC	oying issues . 2129, National Uniformity for Food Act of 1999, b, H.R. 830, H.R. 1145, Country of Origin Labeling, 60412 (11/24/96) Atrazine, Simazine and Cyanazine; Notice of Inititation of Special Review Protection Act	
£7.	Department of Environment	Congress and Federal agencies contacted Cli Check if None of Agriculture tal Protection Agency g Administration presentatives	
18.	Name of each	individual who acted as a lobbyist in this issue area	
	Name	Covered Official Position (if applicable)	New
	Drake, David	1	No
-110000	Haller, Saral	h	No
1-11	Muldoon, Jo-	ę	No
į 19 .	Novartis AG	th foreign entity in the specific issues listed on line 16 above	noration, 40
Sign	ature	Date	
Prim	ted Name and	Title Rachet King - Vice President Page	9 of 20

OBBYING ACTIVITY, Salect gaged in lobbying on behalf of formation as requested. Attach	the client during the report ditional page(s) as need OV (one per page). Law Integrity Act of I ment Act,	1999, Check if None	New
gaged in lobbying on behalf of formation as requested. Attach: General issue area code Specific Lobbying issues H.R. 1778, Federal Election S. 746, Regulatory Improving the proving seed of the proving	the client during the report ditional page(s) as need OV (one per page). Law Integrity Act of I ment Act,	ring period. Using a separate page for each code, provide icd. 1999, Check if None is issue area	New
Specific Lobbying issues H.R. 1778, Federal Electio S. 746, Regulatory Improv House(s) of Congress and Fe House of Representatives Senate Name of each individual who Name Bentley, Liss Drake, David	Law Integrity Act of 1 ment Act, deral agencies contacted	1999, C Check if None is issue area :	New
H.R. 1778, Federal Election S. 746, Regulatory Improved the Francisco of Congress and Federal Election State of Representatives Senate Name of each individual who Name Bentley, Lisa Brake, David	ment Act,	C: Check if None is issue area	New
House of Representatives Senate Name of each individual who Name Bentley, Liss Drake, David		is issue area :	New
Name of each individual who Name Bentley, Lisa Drake, David	acted as a lobbyist in thi	:	New
Nume Bentley, Liss Drake, David	acted as a lobbyist in thi	:	New
Bentley, Lisa Drake, David		Covered Official Position (if applicable)	New
Drake, David			
			No
King, Rachel			No
,			Ne
			-
			-
Interest of each foreign entit Novartis AG To the degree too Nevartis AG, as its par	that public policies, citl	ted on line 16 above D Check if None her laws or regulations, commercially benefit Novartis Corp	peration, so
nature		Date	

Registrant Name;	Novartis		
Client Name:	Novariis Corporation		
mgaged in lobbyin	IVITY. Select as many codes as necessar g on behalf of the client during the reporti ested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide d.	
5. General issue	area code HCR (one per page)	ı.	
 Specific Lobb 	ying issues		
Drug Enforce	ongress and Federal agencies contacted ment Administration Administration resentatives	Check if None	
8. Name of each	individual who acted as a lobbyist in this	issue area	
Name		Covered Official Position (if applicable)	New
Bumbaugb, i	eborah		No
Casserly, Dar)		No
Elkin, James			No
King, Rachel			No
	.,		
Novartis AG	h foreign entity in the specific issues lister To the degree that public policies, eithe AG, as its parent, will benefit.	d on line 16 above C Check if None r laws or regulations, commercially henefit Novaylis Cor	poration, so
ignature		Date	·····

Registrant Nome: Novartis Client Name: Novartis Corporation Data Item Description Snowe/Wyden The Seniors Prescription Insurance Coverage Equity Act 16 Lobbying Issues Breaux/Thomas Medicare Reform Plan Medicare Bi-Partisan Commission Health Insurance Portability and Accssibility Act FDA Modernization Act Pediatric Studies Program Medical Records Privacy- Senators Jeffords, Bennett, Leahy, Kennedy Bills Chairman's Mark (HELP Confidentiality Bills) Xenotransplantation Prospective Payment System Page 12 of 20

Registrant Name:	Novartis	ma	
Client Name:	Novartis Corporation		
engaged in lobbyin	WITY. Select as many codes as necessary to reflect to g on behalf of the client during the reporting period. I lested. Attach additional page(s) as needed.	he general issue areas in which the registrant (sing a separate page for each code, provide	
 General issue Specific Lobb 	area code <u>LBR</u> (one per page) sying issues		
		·	
	,		
17. House(s) of C	ongress and Federal agencies contacted	M Check if None	
18. Name of each	individual who acted as a lobbyist in this issue area		
Name	Covere	l Official Position (if applicable)	New
Name	Covere	l Official Position (if applicable)	New
Name	Covere	l Official Position (if applicable)	New
Name	Сочете	i Official Position (if applicable)	New
Name	Сочеть	l Official Position (if applicable)	New
Name	Соуете	l Official Position (if applicable)	New
Name	Соуете	1 Official Position (if applicable)	New
Name	Соуете	I Official Position (if applicable)	New
	Covere		New
			New
19. Interest of each	th foreign entity in the specific issues listed on line 16	above	
19. Interest of each Signature	th foreign entity in the specific issues listed on line 16	above & Check if None Date	
19. Interest of each Signature	th foreign entity in the specific issues listed on line 16	above & Check if None Date	

Regi	strant Name:	Novartis	
Clien	r Name:	Novartis Corporation	
សមតិវិទាំ	ged in lobbyin	IVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant g on behalf of the client during the reporting period. Using a separate page for each code, provide ested. Attach additional page(s) as needed.	
\6.	H.R. 1115/S. H.R. 1796, M H.R. 1885/S. H.R. 2030, M H.R. 664/S. 7 S. 841, (Kena	ying issues iedicare Full Access to Cancer Treatment Act of 1999, 631, The Intmunosuppressive Drug Coverage Act of 1999, edicare Chronic Disease Prescription Drug Benefit Act of 1999, 1191, The International Prescription Drug Parity Act of 1999, edicare Patient Access to Medical Technology Act of 1999, 31, The Prescription Drug Fairness Act of 1999,	
	Department o	ongress and Federal agencies contacted Check if None of Health & Human Services Administration resentatives	
-	Name of each	individual who acted as a lobbyist in this issue area Covered Official Position (if applicable)	New ***
	Bumbaugh, I	Peborah	No
	Casserly, Dat	ı	No
	Ełkin, James		No
<u>-</u>	King, Rachel		No
;			

	Novartis A.G.	h foreign entity in the specific issues listed on line 16 above — Check if None To the degree that public policies, either laws or regulations, commercially benefit Novariis Cor AG, as its parent, will benefit.	oratioe, so
Signa	iture	Date	
:		Fitle Rachel King · Vice President Page	

Registrant Name:	Novartis		
Client Name:	Novartis Corporation		
engaged in lobbyin		o reflect the general issue areas in which the registrant period. Using a separate page for each code, provide	
 General issue Specific Lobb 	area code <u>NAT</u> (one per page) ying issues		
17. House(s) of C	ongress and Federal agencies contacted	★ Check if None	
18 - X(C	Saultofatora and an expension to apply the		
16. Name of cach	individual who acted as a lobbyist in this iss	sae area	
Name		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Nапи:		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
Name		Covered Official Position (if applicable)	New
			New
	h foreign entity in the specific issues listed of		New
19. Interest of each	h foreign entity in the specific issues listed o		New
19. Interest of each		on line 16 above Check if None	
19. Interest of each		on line I6 above Check if None Date	
19. Interest of each		on line 16 above Check if None	

	Nevartis		
lient Name:	Nevartis Corporation		
ngaged in lobbyin	IVITY. Select as many codes as necessary 3 on behalf of the client during the reportion ested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide l.	
5. General issue	· · · · · · · · · · · · · · · · · · ·		
Specific Lobb	ring issues		
. House(s) of C	ongress and Federal agencies contacted	▼ Check if None	
	mercus mo i caesas agenerica consacion	Ze Check if both	
. Name of each	individual who acted as a lobbyist in this i	issue area	
Nante	ſ	Covered Official Position (if applicable)	New
	· · · · · · · · · · · · · · · · · · ·	(a application)	
. Interest of eac	ı föreign entity in the specific issues listed	on line 16 above Check if None	
. Interest of eac	ı foreign entity in the specific issues listed	Lon line (6 above	
. Interest of eac	ı föreign entity in the specific issues listed	Lon line (6 above	
gnature		Date	
gnature			

Reg	istrant Name:	Novartis		
Clie	ot Name;	Navartis Corporation	VIII	
enga	ged in lobbyin	IVITY. Select as many codes as necessar g on behalf of the client during the reporti ested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, pravide f.	
	General issue Specific Lobb R&D Tax Cr	ying issues		
:				
17.	House(s) of C House of Rep Senate	ongress and Federal agencies contacted resentatives	Cl Check if None	
<u>18</u> .	Name of each	individual who acted as a lobbyist in this	issuc area	
<u></u>	Name		Covered Official Position (if applicable)	New
	Name Drake, David		Covered Official Position (if applicable)	New No
			Covered Official Position (if applicable)	
	Drake, David		Covered Official Position (if applicable)	No
	Drake, David		Covered Official Position (if applicable)	No
	Drake, David		Covered Official Position (if applicable)	No
	Drake, David		Covered Official Position (if applicable)	No
	Drake, David		Covered Official Position (if applicable)	No No
	Drake, David King, Rachel Interest of eac Novartis AG	h foreign entity in the specific issues lister		No No
	Drake, David King, Rachel Interest of eac Novartis AG Ion Novartis	h foreign entity in the specific issues listed To the degree that public policies, eithe AG, as its parent, will benefit.	d on line 16 above	No
Sign	Drake, David King, Rachel Interest of eac Novartis AG Ion Novartis	h foreign entity in the specific issues liste To the degree that public policies, eithe AG, as its parent, will benefit.	d on line 16 above Check if None	No No poration, so

	istrant Name;	Novartis		
Clie	nt Name:	Nevartis Corporation		
enga	aged in lobbyin		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide l.	
		ying issues		
£7.	Department	Administration	. Check if None	
:				
18.	Name of each	individual who acted as a lobbyist in this	issue area	
			I	
	Name		Covered Official Position (if applicable)	New
	Name Haller, Saral]	Covered Official Position (if applicable)	New No
			Covered Official Position (if applicable)	
			Covered Official Position (if applicable)	
			Covered Official Position (if applicable)	
			Covered Official Position (if applicable)	
			Covered Official Position (if applicable)	
			Covered Official Position (if applicable)	
			Covered Official Position (if applicable)	
19.	Haller, Saral	h foreign entity in the specific issues listee		Ne
	Haller, Saral Interest of eac Novartis AC too Novartis	h foreign entity in the specific issues listed To the degree that public policies, eithe AG, as its parent, will benefit.	t on line 16 above	Ne Ne
Sign	Interest of eac Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, eithe AG, as its parent, will benefit.	t on line 16 above	Ne Ne paration, so
Sign	Interest of eac Novartis AG too Novartis	h foreign entity in the specific issues listed To the degree that public policies, eithe AG, as its parent, will benefit.	t on line 16 above	Ne Ne paration, so

Registrant Name:	Novartis		
Client Name:	Nevartis Corporation		
engaged in lobbyin	TVITY. Solect as many codes as necessary to refu g on behalf of the client during the reporting perio tested. Attach additional page(s) as needed.	ect the general issue areas in which the registrant d. Using a separate page for each code, provide	
	area code WAS (one per page)		
Specific Lobb	ying issues		
		·	
17. House(s) of C	ongress and Foderal agencies contacted	★ Check if None	
18. Name of each	individual who acted as a lobbyist in this issue are		
to. Hamo or dadi	morrisda. The series as a record at this issue at	42	
Name	Cov	ered Official Position (if applicable)	New
······································			
	ii ii		
Interest of cac	h foreign entity in the specific issues listed on line	16 above M Check if None	
Pianatana			
		Date	
Printed Name and I	itie Rachel King - Vice President	Pa	ge 19 of 20

legistrant Name:	Novartis				
liem Name:	Novartis Corporation				
ifermation U	pdate Page - Comple	te ONLY where re	egistration information has	changed.	
0. Client new address	5				
t. Chang new princip	val place of business (if different	from line 20)			
Ney	State/Zi	ip (or Country)			
 New general description 	ription of client's business or acti	vities			
LOBBYIST UP 3. Name of each Bentley, Lisa		idual who is no lo n	ger expected to act as a lobb	yist for the client	
•					
SSUE UPDATE					
.4. General lobby	ing issues previously repo	rted that no longer	pertain		
	RGANIZATIONS ving affiliated organization	n(s)			
·····		<u>~.</u>		Principal Place of B	tueinace
	Name	Address		Principal Place of Business (city and state or country)	
			j		
6. Name of each	proviously reported organ	ization that is no le	oger affiliated with the regis	trant or client	
	, , , ,			HAN SA STRUCK	
OREIGN ENT	rrire				
	ving foreign entities				
Name	Ado	dress	Principal Place of Business (city and state or country)	Amount of contribution for tobbying activities	Ownership %
8. Name of each	previously reported foreig	n entity that no lon	! ger owns, or controls, ur is a	J Miliated with the registr	ant client
or affiliated or					
······································	Δ				
gnature	ficht fel	y U	Date	8/13/99	
_	. Puobal King Vine	1	\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
inted Name and Ti	Rachel King - Vice	rresident		Р	age 20 of 20